UNSPSC 51372312: Properidine

This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R1493W1CJ0, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, 1-methylethyl ester but generally known as properidine, which bears US NIH Compound Identifier 62373. European Medicines Agency schedules Properidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10103MIG.

UNSPSC 51372312 Properidine (Commodity) encompasses pharmaceutical products and related medical supplies that state and local governments procure for public health, community health, and pharmacy benefit programs. The recent solicitations under this code show purchasing for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program infrastructure. State and local issuing bodies—including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances—use this code to source critical medications, opioid-reversal agents, and pharmacy inventory across public health facilities, community health centers, and government employee benefit programs.

Activity under the code spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting a date discrepancy in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed to inform future RFP development. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The MMCAP procurement weights price competitiveness at 75 percent of evaluation and requires vendors to maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA).